# Arjuna (à¤…à¤°à¥à¤œà¥à¤¨)

**Sanskrit:** Arjuna (à¤…à¤°à¥à¤œà¥à¤¨), Dhananjaya, Nadisarja, Kakubha, Partha
**Common Names:** Arjun tree, Arjun ki chaal, Koha (Hindi), Marudha Maram (Tamil), Neer Matti (Kannada), Tella Maddi (Telugu)
**Botanical:** *Terminalia arjuna* (Roxb. ex DC.) Wight & Arn.
**Family:** Combretaceae (same family as Haritaki and Bibhitaki)
**Part Used:** Stem bark (primary â€” this is the medicinal part), occasionally leaves and fruits
**Habitat:** Large deciduous tree found along riverbanks and dry watercourses across India. Common in Madhya Pradesh, Uttar Pradesh, Maharashtra.

---

## 1. Overview

Arjuna is Ayurveda's primary cardiac herb. Unlike the other herbs in this database which have broad, multi-system traditional uses, Arjuna has a remarkably focused classical profile: it is predominantly a Hridya (cardiotonic) and Raktapitta-hara (bleeding disorder treatment) herb. This specificity makes it both more clinically defined and more dangerous if misused â€” cardiac pharmacology is not casual territory.

### Classical References

- **Charaka Samhita** â€” Referenced as part of **Udarda Prashamana** (anti-urticaria) and wound healing. Charaka's cardiac references are less explicit than Vagbhata's.
- **Sushruta Samhita** â€” Referenced for Vrana Ropana (wound healing) and Raktapitta.
- **Ashtanga Hridaya (Vagbhata)** â€” The key classical source. Vagbhata describes Arjuna specifically for **Hridroga** (heart disease) and recommends the bark decoction with milk (Ksheerapaka).
- **Bhavaprakasha Nighantu** â€” Monograph describes Hridya (cardiotonic), Raktapitta-hara, Medohara (anti-obesity), and Vrana Ropana properties.
- **Chakradatta** â€” Contains the famous Arjuna Ksheerapaka (Arjuna bark decocted in milk) specifically for cardiac conditions. This is the most cited classical cardiac formulation.

### Traditional Indications
- Hridroga (Heart disease â€” primary classical indication)
- Hridshula (Chest pain / angina equivalent)
- Raktapitta (Bleeding disorders)
- Vrana (Wounds â€” topical)
- Prameha (Metabolic disorders)
- Medoroga (Obesity/lipid disorders)
- Asthikshaya (Bone weakness â€” some references)

### Why This Herb Demands Extra Caution
Arjuna has direct cardiovascular pharmacological effects: inotropic (heart contraction strength), chronotropic (heart rate modulation), and hypotensive. These are the same categories of effects produced by pharmaceutical cardiac drugs (digoxin, beta-blockers, ACE inhibitors). An herb that genuinely affects cardiac function is not a casual supplement â€” it is a pharmacological agent that interacts with the most critical organ system. The risk profile of Arjuna is qualitatively different from, say, Tulsi or Triphala.

---

## 2. Ayurvedic Perspective

| Property | Detail |
|----------|--------|
| **Rasa** (Taste) | Kashaya (Astringent) â€” dominant |
| **Guna** (Qualities) | Laghu (Light), Ruksha (Dry) |
| **Virya** (Potency) | Sheeta (Cooling) |
| **Vipaka** (Post-digestive effect) | Katu (Pungent) |

### Dosha Action
- **Pitta:** Pacifies (Kashaya rasa + Sheeta virya â€” astringent and cooling, ideal for Raktapitta/bleeding)
- **Kapha:** Pacifies (Kashaya rasa + Laghu + Ruksha â€” drying and astringent, reduces Kapha accumulation including Medas/adipose)
- **Vata:** May aggravate. Kashaya rasa + Ruksha guna + Laghu guna + Katu vipaka are all Vata-aggravating qualities. Chronic use without Snigdha (unctuous) vehicle can increase dryness, constipation, and anxiety. This is why the classical Ksheerapaka (milk preparation) is important â€” milk provides Snigdha + Madhura to offset Vata aggravation.

### Hridya Classification
In Ayurveda, Hridya has a specific meaning: it nourishes and strengthens Hridaya (the heart, both as physical organ and as seat of consciousness/emotions). Arjuna is the archetypical Hridya drug. The Ksheerapaka preparation is considered the ideal vehicle because milk (Ksheera) is itself Hridya in Ayurvedic pharmacology â€” creating a synergistic cardiotonic combination.

---

## 3. Modern Pharmacology

### Key Compounds

- **Arjunolic acid** â€” Triterpenoid saponin. Primary cardioactive compound. Antioxidant, anti-atherogenic, cardioprotective in animal models.
- **Arjunic acid** â€” Triterpenoid. Anti-inflammatory, anti-atherogenic.
- **Arjunone** â€” Flavonoid. Antioxidant, vasodilatory.
- **Arjunolone** â€” Flavonoid. Antioxidant.
- **Terminic acid** â€” Triterpenoid.
- **Tannins** (Oligomeric proanthocyanidins â€” OPCs) â€” 15-20% of bark. Antioxidant, astringent. Similar class to grape seed extract OPCs.
- **Casuarinin, Casuariin** â€” Hydrolysable tannins. Antioxidant.
- **Beta-sitosterol** â€” Phytosterol. Cholesterol-modulating.
- **Calcium, Zinc, Magnesium, Copper** â€” Notable mineral content in bark.

### Cardiovascular Mechanisms

**Positive inotropic effect:**
Arjunolic acid and related saponins increase myocardial contractility â€” the heart pumps more effectively. This is pharmacologically similar (though milder) to cardiac glycosides like digoxin. Animal studies show increased left ventricular ejection fraction.

**Hypotensive / Vasodilatory:**
Endothelium-dependent vasodilation (nitric oxide pathway). Reduces peripheral vascular resistance. Modest blood pressure reduction in animal models and small human trials.

**Anti-atherogenic:**
Reduces oxidation of LDL cholesterol (a key step in plaque formation). OPCs and arjunolic acid are potent lipid antioxidants.

**Anti-ischemic:**
Reduces myocardial oxygen consumption while maintaining contractility â€” favourable balance for angina-like conditions. Animal models show reduced infarct size.

**Mild chronotropic effect:**
Some evidence of heart rate modulation (can slow heart rate). Mechanism not fully characterised â€” possible vagal or calcium channel effects.

### Evidence Table

| Claim | Evidence Level | Notes |
|-------|---------------|-------|
| Stable angina (chest pain reduction) | **B** | Several small RCTs (Bharani 2002, Manchanda 1996). Reduced angina frequency and improved exercise tolerance. Most trials compare to placebo, not to standard angina drugs (nitrates, beta-blockers). Promising but underpowered. |
| Heart failure (ejection fraction improvement) | **B** | Small trials show improved LVEF (left ventricular ejection fraction) and exercise capacity. Bharani 1995 showed improvement comparable to isosorbide mononitrate in some parameters. Not tested against modern HF drugs (ACE inhibitors, beta-blockers, ARNI). |
| Lipid modulation (cholesterol) | **B** | Small trials show total cholesterol and LDL reduction, HDL improvement. Consistent direction. Modest effect size. Not a statin replacement. |
| Blood pressure reduction | **B-C** | Small trials + animal data. Modest reduction (~5-10 mmHg systolic). Not a primary antihypertensive. |
| Antioxidant (cardiovascular) | **B-C** | Reduced oxidised LDL markers in small trials. OPCs well-characterised as lipid antioxidants. |
| Endothelial function improvement | **C** | Animal and small human studies. Improved flow-mediated dilation. |
| Anti-arrhythmic | **C** | Animal data shows anti-arrhythmic effects. No human trials specifically for arrhythmia. |
| Anti-diabetic | **C** | Some blood glucose lowering in animal models. Very limited human data. Not a primary anti-diabetic. |
| Bone strength (Osteoporosis) | **C-D** | Limited animal data. Calcium + mineral content provides nutritional rationale, not pharmacological evidence. |
| Post-MI recovery | **C** | Animal studies on infarct size reduction. No human post-MI trials. |
| Heart attack prevention | **D** | No evidence. Extrapolation from anti-atherogenic and anti-oxidant data. Not a proven preventive. |

---

## 4. Safe Usage Ranges (Educational Only)

> **"This is general educational information, not a medical prescription. Arjuna has direct cardiovascular effects. Do not self-prescribe for heart conditions."**

| Form | Typical Adult Range | Notes |
|------|---------------------|-------|
| **Bark powder (Churna)** | 3-6 g/day | Classical form. Traditionally prepared as Ksheerapaka (decocted in milk). |
| **Arjuna Ksheerapaka** | 3-5 g bark boiled in 200ml milk + 200ml water, reduced to milk volume | The classical cardiac preparation. Taken once or twice daily. |
| **Standardised extract** | 500-1000 mg/day | Commercial preparations. Standardisation varies (often to arjunolic acid or tannin content). |
| **Arjunarishta** | 15-30 ml twice daily | Classical fermented preparation. Contains self-generated alcohol (~5-10%). Traditional cardiac tonic. |
| **Decoction (Kwath)** | 50-100 ml/day | Water decoction. Less traditional for cardiac use than Ksheerapaka. |

### Critical Dosing Notes
- **Do NOT self-dose for active heart disease.** If you have diagnosed heart failure, angina, arrhythmia, or any cardiac condition, Arjuna should be used under the supervision of both a cardiologist and a qualified Ayurvedic practitioner.
- **Do NOT use Arjuna as a substitute for prescribed cardiac medication** (beta-blockers, ACE inhibitors, statins, antiplatelets) without physician guidance.
- **The Ksheerapaka preparation matters.** Milk provides a lipid vehicle for triterpenoid absorption and counterbalances the Vata-aggravating (drying) properties. Water decoction alone may be less effective and more Vata-aggravating.

---

## 5. Risk Coding

| Condition | Risk Code | Explanation |
|-----------|-----------|-------------|
| **Active heart disease** (heart failure, angina, post-MI) | ðŸ”´ **Avoid Unless Supervised** | Arjuna has real cardiac effects. In active heart disease, any unmonitored inotropic, chronotropic, or hypotensive agent adds unpredictable variables to an already-critical system. Must be used under cardiologist + Vaidya dual supervision. |
| **On cardiac medications** (beta-blockers, ACE inhibitors, digoxin, nitrates, anti-arrhythmics) | ðŸ”´ **Avoid Unless Supervised** | Additive hemodynamic effects. Arjuna + beta-blocker = excessive heart rate reduction. Arjuna + digoxin = additive inotropic effect with toxicity risk. Arjuna + ACE inhibitor = compounded hypotension. Every combination requires physician awareness. |
| **Bradycardia** | ðŸŸ¡â€“ðŸ”´ **Caution to Avoid** | Mild chronotropic (heart rate slowing) properties. In pre-existing bradycardia or sick sinus syndrome, additional heart rate reduction is dangerous. |
| **Hypotension** | ðŸŸ¡ **Use With Caution** | Vasodilatory and hypotensive effects. Additive with antihypertensives. May cause dizziness, lightheadedness, or syncope. |
| **Pregnancy** | ðŸ”´ **Avoid Unless Supervised** | No safety data. Cardiac-active herb â€” not appropriate for pregnancy self-medication. |
| **Lactation** | ðŸŸ¡ **Use With Caution** | No data. Conservative approach. |
| **Diabetes on medication** | ðŸŸ¡ **Use With Caution** | Mild blood sugar lowering in some data. Monitor. |
| **Blood thinners** | ðŸŸ¡ **Use With Caution** | Tannin/OPC content has mild antiplatelet properties. Monitor if on Warfarin/Aspirin. |
| **Children** | ðŸ”´ **Avoid** | No paediatric indication or safety data. Cardiac-active herbs are not for children. |
| **Kidney disease** | ðŸŸ¡ **Use With Caution** | Hemodynamic effects may affect renal perfusion. In CKD, any blood pressure/cardiac output change needs monitoring. |
| **Scheduled surgery** | ðŸŸ¡ **Discontinue 2 weeks before** | Cardiac and hemodynamic effects + mild antiplatelet activity. |
| **Healthy individuals without cardiac concerns** | ðŸŸ¡ **Questionable benefit** | Arjuna is primarily a cardiac herb. Using it preventively in healthy young adults without cardiac risk factors has limited rationale and introduces unnecessary pharmacological exposure. Not every herb needs to be taken by everyone. |

---

## 6. Side Effects

### Common
- GI discomfort (astringent taste causes nausea in some)
- Mild headache
- Constipation (Kashaya rasa + Ruksha guna â€” astringent drying effect on bowel)
- Dryness of mouth/skin with chronic use

### Uncommon
- Hypotension symptoms (dizziness, lightheadedness, fatigue) â€” especially if combined with antihypertensives
- Bradycardia (slowed heart rate) â€” usually subclinical at standard doses
- Increased bleeding tendency (mild, at higher doses)

### Rare
- Excessive hypotension/syncope (if combined with cardiac drugs without monitoring)
- Allergic reaction
- GI bleeding (theoretical â€” tannin irritation + antiplatelet effect in susceptible individuals)

---

## 7. Drug Interactions

| Drug / Category | Risk | Mechanism |
|----------------|------|-----------|
| **Beta-blockers** (Metoprolol, Atenolol, Propranolol) | **High** | Additive negative chronotropy (heart rate reduction) + additive hypotension. Risk of symptomatic bradycardia and hypotension. |
| **Digoxin** | **High** | Additive positive inotropic effect. Risk of digoxin-like toxicity (nausea, visual disturbances, arrhythmia). Digoxin has a narrow therapeutic index â€” any additive inotropic agent is high-risk. |
| **ACE inhibitors / ARBs** (Enalapril, Losartan, Telmisartan) | **Moderate-High** | Additive hypotension. May cause symptomatic low BP (dizziness, syncope). |
| **Calcium channel blockers** (Amlodipine, Diltiazem, Verapamil) | **Moderate-High** | Additive vasodilation (Amlodipine) or additive heart rate reduction (Diltiazem, Verapamil). |
| **Nitrates** (Isosorbide mononitrate/dinitrate, GTN) | **Moderate** | Additive vasodilation and hypotension. |
| **Anti-arrhythmics** (Amiodarone, Flecainide) | **Moderate-High** | Unpredictable additive effects on cardiac rhythm. Amiodarone has complex pharmacology â€” any additive agent requires ECG monitoring. |
| **Antidiabetic drugs** | **Low-Moderate** | Mild additive blood sugar reduction. |
| **Anticoagulants/Antiplatelets** | **Low-Moderate** | Mild antiplatelet activity from tannins/OPCs. Monitor if on Warfarin. |
| **Diuretics** | **Moderate** | Additive hypotension + potential electrolyte effects. |
| **Iron supplements** | **Moderate** | High tannin content chelates iron. Separate by 2+ hours. |
| **Thyroid medications** | **Low** | Tannins may reduce absorption. Separate by 2-4 hours. |

**CRITICAL: Arjuna interacts with the majority of cardiovascular drugs.** Any patient on cardiac medication must inform their cardiologist before starting Arjuna. This is not optional â€” it is a safety-critical requirement.

---

## 8. Misuse Patterns in India

### Pattern 1: Self-Prescribing for Heart Symptoms
Patients experience chest pain, palpitations, or breathlessness and take Arjuna bark instead of seeking cardiological evaluation. Arjuna may provide symptomatic relief (mild anti-anginal effect), which delays diagnosis of potentially life-threatening conditions (acute coronary syndrome, arrhythmia, valvular heart disease). Symptomatic relief â‰  disease treatment.

### Pattern 2: Replacing Cardiac Medications
Patients on prescribed cardiac drugs (beta-blockers, statins, ACE inhibitors) stop their medication and switch to Arjuna based on "natural is better" reasoning or advice from non-medical sources. This is acutely dangerous for conditions like heart failure, post-MI management, or atrial fibrillation where pharmaceutical adherence is life-critical.

### Pattern 3: Preventive Overconsumption
Healthy individuals with family history of heart disease take Arjuna daily "for prevention." There is no evidence that Arjuna prevents cardiac events in healthy populations. Unnecessary chronic exposure to a cardiac-active herb adds side effect risk without proven benefit.

### Pattern 4: Arjunarishta as Tonic
Arjunarishta (fermented preparation containing ~5-10% self-generated alcohol) is widely available OTC and taken as a general "heart tonic." The alcohol content means it interacts with sedatives, hepatotoxic drugs, and antidiabetic medications. Users rarely consider the alcohol component.

---

## 9. When to See a Doctor

- **Chest pain, breathlessness, or palpitations** â€” THESE ARE CARDIAC EMERGENCIES. Do not treat with Arjuna. Seek immediate medical evaluation.
- **Dizziness, fainting, or syncope** while taking Arjuna â€” may indicate excessive hypotension or bradycardia
- **Slow heart rate** (<60 bpm with symptoms) â€” stop Arjuna, seek ECG evaluation
- **Any cardiac medication change** â€” do not adjust Arjuna dose as a compensatory measure without physician input
- **Before starting Arjuna with any cardiac drug** â€” cardiologist must be informed
- **Leg swelling, sudden weight gain, worsening breathlessness** â€” signs of heart failure decompensation. Seek urgent care.

---

## References

- Ashtanga Hridaya â€” Hridroga Chikitsa references
- Chakradatta â€” Arjuna Ksheerapaka formulation
- Bhavaprakasha Nighantu â€” Arjuna monograph
- Bharani A, et al. (2002). "Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure." *Int J Cardiol*, 85(1):1-8.
- Bharani A, et al. (1995). "Terminalia arjuna in chronic stable angina." *Indian Heart J*, 47(4):326.
- Manchanda SC, et al. (1996). "Arjuna in the management of coronary artery disease." *Indian Heart J*, 48(5):533.
- Dwivedi S, Agarwal MP. (1994). "Antianginal and cardioprotective effects of Terminalia arjuna." *J Assoc Physicians India*, 42(9):721-722.
- Kapoor D, et al. (2014). "Terminalia arjuna: A comprehensive review." *J Pharmacogn Phytochem*, 3(4).

---

*Entry prepared following the Ayurv Educational Framework v2. Last updated: 2026-02-16.*
*This content is for educational purposes only and is not a substitute for professional medical advice. Herbal products can interact with modern medicines and medical conditions.*
